The neurobiology of APOE in schizophrenia and mood disorders

Frontiers in Bioscience

Volumn 16, Issue 3, 2011, Pages 962-979

  Gibbons, Andrew Stuart ^a,b   Udawela, Madhara ^a,b   Jeon, Won Je ^a   Suk Seo, Myoung ^a,b   Brooks, Lucy ^a,b,c   Dean, Brian ^a,b,d  

^a FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^d MONASH UNIVERSITY   (Australia)

Author keywords

Apoliprotein E; Bipolar disorder; Depression; Low density lipoprotein receptor; Review; Schizophrenia

Indexed keywords

APOLIPOPROTEIN E; LOW DENSITY LIPOPROTEIN RECEPTOR; NERVE CELL ADHESION MOLECULE; NERVE PROTEIN; REELIN PROTEIN; SCLEROPROTEIN; SERINE PROTEINASE;

ALZHEIMER DISEASE; BIPOLAR DISORDER; CENTRAL NERVOUS SYSTEM; COGNITION; DRUG EFFECT; GENETICS; GLIA; HUMAN; LIPID METABOLISM; MAJOR DEPRESSION; METABOLISM; MOOD DISORDER; MYELIN SHEATH; NERVE CELL PLASTICITY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SYNAPSE;

ALZHEIMER DISEASE; APOLIPOPROTEINS E; BIPOLAR DISORDER; CELL ADHESION MOLECULES, NEURONAL; CENTRAL NERVOUS SYSTEM; COGNITION; DEPRESSIVE DISORDER, MAJOR; EXTRACELLULAR MATRIX PROTEINS; HUMANS; LIPID METABOLISM; MOOD DISORDERS; MYELIN SHEATH; NERVE TISSUE PROTEINS; NEUROGLIA; NEURONAL PLASTICITY; RECEPTORS, LDL; SCHIZOPHRENIA; SERINE ENDOPEPTIDASES; SIGNAL TRANSDUCTION; SYNAPSES;

EID: 79955040875     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/3729     Document Type: Review

References (202)

1. L. M. Fleming, K. H. Weisgraber, W. J. Strittmatter, J. C. Troncoso and G. V. W. Johnson: Differential binding of apolipoprotein E isoforms to tau and other cytoskeletal proteins. Exper Neurol 138, 252-260 (1996) (Pubitemid 26135201)
2. D. Flaherty, Q. Lu, J. Soria and J. G. Wood: Regulation of tau phosphorylation in microtubule fractions by apolipoprotein E. J Neurosci Res 56, 271-274 (1999) (Pubitemid 29210617)
3. K. M. Korwek, J. H. Trotter, M. J. Ladu, P. M. Sullivan and E. J. Weeber: ApoE isoform-dependent changes in hippocampal synaptic function. Mol Neurodegen 4, 21 (2009)
4. A. M. Fagan, G. Bu, Y. Sun, A. Daugherty and D. M. Holtzman: Apolipoprotein E-containing high density lipoprotein promotes neurite outgrowth and is a ligand for the low density lipoprotein receptor-related protein. J Biol Chem 271, 30121-30125 (1996) (Pubitemid 26389653)
5. Y. J. Zhu and D. Y. Hui: Apolipoprotein E binding to low density lipoprotein receptor-related protein-1 inhibits cell migration via activation of cAMP-dependent protein kinase A. J Biol Chem, 278, 36257-36263 (2003) (Pubitemid 37139949)
6. K. Tamai, M. Semenov, Y. Kato, R. Spokony, C. M. Liu, Y. Katsuyama, F. Hess, J. P. Saint-Jeannet and X. He: LDL receptor-related proteins in Wnt signal transduction. Nature, 407, 530-535 (2000)
7. A. M. Saunders, W. J. Strittmatter, D. Schmechel, P. H. George-Hyslop, M. A. Pericak-Vance, S. H. Joo, B. L. Rosi, J. F. Gusella, D. R. Crapper-MacLachlan, M. J. Alberts and et al.: Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology, 43, 1467-72 (1993) (Pubitemid 23230526)
8. E. H. Corder, A. M. Saunders, W. J. Strittmatter, D. E. Schmechel, P. C. Gaskell, G. W. Small, A. D. Roses, J. L. Haines and M. A. Pericak-Vance: Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science, 261, 921-923 (1993) (Pubitemid 23275809)
9. E. H. Corder, A. M. Saunders, N. J. Risch, W. J. Strittmatter, D. E. Schmechel, P. C. Gaskell, Jr., J. B. Rimmler, P. A. Locke, P. M. Conneally, K. E. Schmader and et al.: Protective effect of apolipoprotein E type 2 allele for late onset alzheimer disease. Nature Genetics 7, 180-184 (1994) (Pubitemid 24174658)
10. C. R. Harrington, M. Roth, J. H. Xuereb, P. J. McKenna and C. M. Wischik: Apolipoprotein E type epsilon4 allele frequency is increased in patients with schizophrenia. Neurosci Lett, 202, 101-104 (1995) (Pubitemid 26011567)
11. E. D. Caine, J. M. Lyness and D. A. King: Reconsidering Depression in the Elderly. Am J Geriatr Psychiatry 1, 4-20 (1993)
12. S. C. Rall, K. H. Weisgraber and R. W. Mahley: Human apolipoprotein-E - The complete amino-acid-sequence. J Biol Chem, 257, 4171-4178 (1982)
13. J. D. Smith, A. Melian, T. Leff and J. L. Breslow: Expression of the human apolipoprotein-E gene is regulated by multiple positive and negative elements. J Biol Chem, 263, 8300-8308 (1988)
14. C. J. N. Rall, J. M. Hoeg, R. E. Gregg, S. W. Law, J. C. Monge, M. S. Meng, L. A. Zech and H. B. Brewer: Enhanced apolipoprotein-E production with normal hepatic messenger-RNA levels in the watanabe heritable hyperlipidemic rabbit. Arteriosclerosis, 8, 804-809 (1988) (Pubitemid 19005368)
15. A. Lalazar, K. H. Weisgraber, S. C. Rall, H. Giladi, T. L. Innerarity, A. Z. Levanon, J. K. Boyles, B. Amit, M. Gorecki, R. W. Mahley and T. Vogel: Site-specific mutagenesis of human apolipoprotein-E - Receptor-binding activity of variants with single amino-acid substitutions. J Biol Chem, 263, 3542-3545 (1988) (Pubitemid 18078938)
16. M. Zaiou, K. S. Arnold, Y. M. Newhouse, T. L. Innerarity, K. H. Weisgraber, M. L. Segall, M. C. Phillips and S. Lund-Katz: Apolipoprotein E-low density lipoprotein receptor interaction: influences of basic residue and amphipathic alphahelix organization in the ligand. J Lipid Res, 41, 1087-1095 (2000) (Pubitemid 30483013)
17. V. I. Zannis, J. L. Breslow, G. Utermann, R. W. Mahley, K. H. Weisgraber, R. J. Havel, J. L. Goldstein, M. S. Brown, G. Schonfeld, W. R. Hazzard and C. Blum: Proposed nomenclature of apoE-isoproteins, apoE-genotypes, and phenotypes. J Lipid Res, 23, 911-914 (1982) (Pubitemid 13244364)
18. R. N. Martins, R. Clarnette, C. Fisher, G. A. Broe, W. S. Brooks, P. Montgomery and S. E. Gandy: ApoE genotypes in Australia: roles in early and late onset alzheimer's disease and Down's syndrome. Neuroreport, 6, 1513-1516 (1995)
19. K. H. Weisgraber, T. L. Innerarity and R. W. Mahley: Abnormal lipoprotein receptor-binding activity of the human-E apoprotein due to cysteine-arginine interchange at a single site. J Biol Chem 257, 2518-2521 (1982)
20. R. B. DeMattos, L. L. Rudel and D. L. Williams: Biochemical analysis of cell-derived apoE3 particles active in stimulating neurite outgrowth. J Lipid Res, 42, 976-987 (2001) (Pubitemid 32545854)
21. B. P. Nathan, S. Bellosta, D. A. Sanan, K. H. Weisgraber, R. W. Mahley and R. E. Pitas: Differentialeffects of apolipoproteins E3 and E4 on neuronal growth invitro. Science 264, 850-852 (1994) (Pubitemid 24193454)
22. S. Bellosta, B. P. Nathan, M. Orth, L. M. Dong, R. W. Mahley and R. E. Pitas: Stable expression and secretion of apolipoproteins E3 and E4 in mouse neuroblastoma-cells produces differential-effects on neurite outgrowth. J Biol Chem, 270, 27063-27071 (1995)
23. S. C. Rall, K. H. Weisgraber, T. L. Innerarity, T. P. Bersot, C. B. Blum and R. W. Mahley: Identification of a new structural variant of human apolipoprotein-E, E2(Lys146→Gln), in a type-III hyperlipoproteinemic subject with the E3/2 phenotype. J Clin Invest, 72, 1288-1297 (1983) (Pubitemid 13013761)
24. P. Deknijff, A. Vandenmaagdenberg, R. R. Frants and L. M. Havekes: Genetic-heterogeneity of apolipoprotein-E and its influence on plasma-lipid and lipoprotein levels. Hum Mutat, 4, 178-194 (1994) (Pubitemid 24319486)
25. P. Deknijff, A. Vandenmaagdenberg, A. F. H. Stalenhoef, J. A. G. Leuven, P. N. M. Demacker, L. P. Kuyt, R. R. Frants and L. M. Havekes: Familial dysbetalipoproteinemia associated with apolipoprotein E3-leiden in an extended multigeneration pedigree. J Clin Invest, 88, 643-655 (1991)
26. M. Guttman, J. H. Prieto, J. E. Croy and E. A. Komives: Decoding of Lipoprotein-Receptor Interactions: Properties of Ligand Binding Modules Governing Interactions with Apolipoprotein E. Biochemistry, 49, 1207-1216 (2010)
27. S. Takahashi, Y. Kawarabayasi, T. Nakai, J. Sakai and T. Yamamoto: Rabbit very low-density-lipoprotein receptor - a low-density-lipoprotein receptor-like protein with distinct ligand specificity. Proc Natl Acad Sci USA, 89, 9252-9256 (1992)
28. U. Beisiegel, W. Weber, G. Ihrke, J. Herz and K. K. Stanley: The LDL receptor related protein, LRP, is an apolipoprotein E-binding protein. Nature, 341, 162-164 (1989) (Pubitemid 19222781)
29. M. Z. Kounnas, E. B. Loukinova, S. Stefansson, J. A. K. Harmony, B. H. Brewer, D. K. Strickland and W. S. Argraves: Identification of glycoprotein-330 as an endocytic receptor for apolipoprotein-J/clusterin. J Biol Chem, 270, 13070-13075 (1995)
30. Y. Lu, Q. B. Tian, S. Endo and T. Suzuki: A role for LRP4 in neuronal cell viability is related to apoE-binding. Brain Res, 1177, 19-28 (2007) (Pubitemid 47561888)
31. D. H. Kim, H. Iijima, K. Goto, J. Sakai, H. Ishii, H. J. Kim, H. Suzuki, H. Kondo, S. Saeki and T. Yamamoto: Human apolipoprotein E receptor 2 - A novel lipoprotein receptor of the low density lipoprotein receptor family predominantly expressed in brain. J Biol Chem, 271, 8373-8380 (1996)
32. T. Sugiyama, H. Kumagai, Y. Morikawa, Y. Wada, A. Sugiyama, K. Yasuda, N. Yokoi, S. Tamura, T. Kojima, T. Nosaka, E. Senba, S. Kimura, T. Kadowaki, T. Kodama and T. Kitamura: A novel low-density lipoprotein receptor-related protein mediating cellular uptake of apolipoprotein E-enriched beta-VLDL in vitro. Biochemistry 39, 15817-15825 (2000) (Pubitemid 32038242)
33. K. Taira, H. Bujo, S. Hirayama, H. Yamazaki, T. Kanaki, K. Takahashi, I. Ishii, T. Miida, W. J. Schneider and Y. Saito: LR11, a mosaic LDL receptor family member, mediates the uptake of ApoE-rich lipoproteins in vitro. Arterioscl Thromb Vascular Biol, 21, 1501-1506 (2001) (Pubitemid 34219815)
34. F. T. Yen, C. J. Mann, L. M. Guermani, N. F. Hannouche, N. Hubert, C. A. Hornick, V. N. Bordeau, G. Agnani and B. E. Bihain: Identification of a lipolysis-stimulated receptor that is distinct from the LDL receptor and the LDL receptor-related protein. Biochemistry, 33, 1172-1180 (1994) (Pubitemid 24072447)
35. H. Ishii, D. H. Kim, T. Fujita, Y. Endo, S. Saeki and T. T. Yamamoto: cDNA cloning of a new low-density lipoprotein receptor-related protein and mapping of its gene (LRP3) to chromosome bands 19q12-q13.2. Genomics 51, 132-135 (1998) (Pubitemid 28373382)
36. J. Herz, Y. Chen, I. Masiulis and L. Zhou: Expanding functions of lipoprotein receptors. J Lipid Res, 50 Suppl, S287-92 (2009)
37. Y. Li, J. Cam and G. Bu: Low-density lipoprotein receptor family: endocytosis and signal transduction. Mol Neurobiol, 23(1), 53-67 (2001) (Pubitemid 32948272)
38. P. May, E. Woldt, R. L. Matz and P. Boucher: The LDL receptor-related protein (LRP) family: an old family of proteins with new physiological functions. Ann Med, 39, 219-28 (2007) (Pubitemid 46676481)
39. P. May, J. Herz and H. H. Bock: Molecular mechanisms of lipoprotein receptor signalling. Cell Mol Life Sci, 62(19-20), 2325-2338 (2005) (Pubitemid 41500548)
40. G. D'Arcangelo, R. Homayouni, L. Keshvara, D. S. Rice, M. Sheldon and T. Curran: Reelin is a ligand for lipoprotein receptors. Neuron 24, 471-479 (1999) (Pubitemid 29508420)
41. F. Impagnatiello, A. R. Guidotti, C. Pesold, Y. Dwivedi, H. Caruncho, M. G. Pisu, D. P. Uzunov, N. R. Smalheiser, J. M. Davis, G. N. Pandey, G. D. Pappas, P. Tueting, R. P. Sharma and E. Costa: A decrease of reelin expression as a putative vulnerability factor in schizophrenia. Proc Natl Acad Sci USA, 95, 15718-15723 (1998) (Pubitemid 29018766)
42. Y. Chen, U. Beffert, M. Ertunc, T. S. Tang, E. T. Kavalali, I. Bezprozvanny and J. Herz: Reelin modulates NMDA receptor activity in cortical neurons. J Neurosci, 25, 8209-8216 (2005) (Pubitemid 41292115)
43. Z. Y. Sheng, M. Prorok, B. E. Brown and F. J. Castellino: N-methyl-D-aspartate receptor inhibition by an apolipoprotein E-derived peptide relies on low-density lipoprotein receptor-associated protein. Neuropharmacology, 55, 204-214 (2008)
44. F. Panza, V. Solfrizzi, A. M. Colacicco, A. M. Basile, A. D'Introno, C. Capurso, M. Sabba, S. Capurso and A. Capurso: Apolipoprotein E (APOE) polymorphism influences serum APOE levels in Alzheimer's disease patients and centenarians. Neuroreport, 14, 605-608 (2003) (Pubitemid 36528999)
45. R. W. Mahley: Atherogenic hyperlipoproteinemia. The cellular and molecular biology of plasma lipoproteins altered by dietary fat and cholesterol. Med Clin North Am 66(2), 375-402 (1982) (Pubitemid 12115372)
46. J. E. Eichner, S. T. Dunn, G. Perveen, D. M. Thompson, K. E. Stewart and B. C. Stroehla: Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. Am J Epidemiol 155, 487-495 (2002) (Pubitemid 34208040)
47. R. E. Pitas, J. K. Boyles, S. H. Lee, D. Hui and K. H. Weisgraber: Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B,E(LDL) receptors in the brain. J Biol Chem, 262, 14352-60 (1987) (Pubitemid 17152101)
48. J. E. Vance, H. Hayashi and B. Karten: Cholesterol homeostasis in neurons and glial cells. Semin Cell Dev Biol, 16, 193-212 (2005) (Pubitemid 40432121)
49. J. Poirier, A. Baccichet, D. Dea and S. Gauthier: Cholesterol synthesis and lipoprotein reuptake during synaptic remodelling in hippocampus in adult rats. Neuroscience, 55, 81-90 (1993) (Pubitemid 23194987)
50. D. I. Graham, K. Horsburgh, J. A. Nicoll and G. M. Teasdale: Apolipoprotein E and the response of the brain to injury. Acta Neurochir Suppl, 73, 89-92 (1999)
51. R. W. Mahley, K. H. Weisgraber and Y. Huang: Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc Natl Acad Sci USA, 103, 5644-5651 (2006)
52. N. A. Elshourbagy, W. S. Liao, R. W. Mahley and J. M. Taylor: Apolipoprotein-E mRNA is abundant in the brain and adrenals, as well as in the liver, and is present in other peripheral-tissues of rats and marmosets. Proc Natl Acad Sci USA, 82, 203-207
53. J. K. Boyles, R. E. Pitas, E. Wilson, R. W. Mahley and J. M. Taylor: Apolipoprotein-E associated with astrocytic glia of the central nervous-system and with nonmyelinating glia of the peripheral nervous-system. J Clinl Invest, 76, 1501-1513 (1985) (Pubitemid 16193568)
54. J. Poirier, M. Hess, P. C. May and C. E. Finch: Astrocytic apolipoprotein-E messenger-RNA and GFAP messenger-RNA in hippocampus after entorhinal cortex lesioning. Mol Brain Res, 11, 97-106 (1991)
55. S. H. Han, G. Einstein, K. H. Weisgraber, W. J. Strittmatter, A. M. Saunders, M. Pericakvance, A. D. Roses and D. E. Schmechel: Apolipoprotein-E is localized to the cytoplasm of human cortical-neurons - a light and electronmicroscopic study. J Neuropathol Exp Neurol, 53, 535-544 (1994) (Pubitemid 24276812)
56. F. Bao, H. Arai, S. Matsushita, S. Higuchi and H. Sasaki: Expression of apolipoprotein E in normal and diverse neurodegenerative disease brain. Neuroreport, 7, 1733-1739 (1996) (Pubitemid 26348246)
57. R. E. Metzger, M. J. LaDu, J. B. Pan, G. S. Getz, D. E. Frail and M. T. Falduto: Neurons of the human frontal cortex display apolipoprotein E immunoreactivity: Implications for Alzheimer's disease. J Neuropathol Exp Neurol, 55, 372-380 (1996) (Pubitemid 26085587)
58. P. T. Xu, J. R. Gilbert, H. L. Qiu, J. Ervin, T. R. Rothrock-Christian, C. Hulette and D. E. Schmechel: Specific regional transcription of apolipoprotein E in human brain neurons. Am J Pathol,154, 601-611 (1999) (Pubitemid 29094109)
59. A. Araque, V. Parpura, R. P. Sanzgiri and P. G. Haydon: Tripartite synapses: glia, the unacknowledged partner. Trends Neurosci, 22, 208-215 (1999) (Pubitemid 29202082)
60. E. J. Weeber, U. Beffert, C. Jones, J. M. Christian, E. Forster, J. D. Sweatt and J. Herz: Reelin and ApoE receptors cooperate to enhance hippocampal synaptic plasticity and learning. J Biol Chem, 277, 39944-39952 (2002) (Pubitemid 35190981)
61. J. L. Tu, C. B. Zhao, T. Vollmer, S. Coons, H. J. Lin, S. Marsh, D. M. Treiman and J. Shi: APOE 4 polymorphism results in early cognitive deficits in an EAE model. Biochem Biophys Res Commun, 384, 466-470 (2009)
62. D. H. Mauch, K. Nagler, S. Schumacher, C. Goritz, E. C. Muller, A. Otto and F. W. Pfrieger: CNS synaptogenesis promoted by glia-derived cholesterol. Science, 294, 1354-1357 (2001) (Pubitemid 33063104)
63. D. S. Janowsky, M. K. el-Yousef, J. M. Davis and H. J. Sekerke: A cholinergicadrenergic hypothesis of mania and depression. Lancet, 2, 632-635 (1972)
64. A. S. Gibbons, E. Scarr, C. McLean, S. Sundram and B. Dean: Decreased muscarinic receptor binding in the frontal cortex of bipolar disorder and major depressive disorder subjects. J Affect Disord, 116, 184-191 (2009)
65. E. Scarr, T. F. Cowie, S. Kanellakis, S. Sundram, C. Pantelis and B. Dean: Decreased cortical muscarinic receptors define a subgroup of subjects with schizophrenia. Mol Psychiatry, 14, 1017-1023, (2009) :
66. E. Scarr, M. Beneyto, J. H. Meador-Woodruff and B. Dean: Cortical glutamatergic markers in schizophrenia. Neuropsychopharmacology, 30, 1521-1531 (2005) (Pubitemid 41153124)
67. E. Scarr, G. Pavey, S. Sundram, A. MacKinnon and B. Dean: Decreased hippocampal NMDA, but not kainate or AMPA receptors in bipolar disorder. Bipolar Disord. 5, 257-264 (2003) (Pubitemid 37009889)
68. D. H. Mauch, K. Nagler, S. Schumacher, C. Goritz, E. C. Muller, A. Otto and F. W. Pfrieger: CNS synaptogenesis promoted by glia-derived cholesterol. Science, 294, 1354-1357 (2001) (Pubitemid 33063104)
69. H. S. Hoe, D. C. Harris and G. W. Rebeck: Multiple pathways of apolipoprotein E signaling in primary neurons. J Neurochem, 93, 145-155 (2005) (Pubitemid 40463524)
70. H. S. Hoe, A. Pocivavsek, H. Dai, G. Chakraborty, D. C. Harris and G. W. Rebeck: Effects of apoE on neuronal signaling and APP processing in rodent brain. Brain Res, 1112, 70-79 (2006) (Pubitemid 44344621)
71. P. M. Sullivan, H. Mezdour, Y. Aratani, C. Knouff, J. Najib, R. L. Reddick, S. H. Quarfordt and N. Maeda: Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. J Biol Chem, 272, 17972-17980 (1997) (Pubitemid 27306374)
72. B. L. Trommer, C. Shah, S. H. Yun, G. Gamkrelidze, E. S. Pasternak, G. L. Ye, M. Sotak, P. M. Sullivan, J. F. Pasternak and M. J. LaDu: ApoE isoform affects LTP in human targeted replacement mice. Neuroreport, 15, 2655-2658 (2004) (Pubitemid 40053957)
73. G. Bartzokis, P. H. Lu, D. H. Geschwind, K. Tingus, D. Huang, M. F. Mendez, N. Edwards and J. Mintz: Apolipoprotein E affects both myelin breakdown and cognition: implications for age-related trajectories of decline into dementia. Biol Psychiatry, 62, 1380-1387 (2007) (Pubitemid 350180726)
74. Z. Qiu, B. T. Hyman and G. W. Rebeck: Apolipoprotein E receptors mediate neurite outgrowth through activation of p44/42 mitogen-activated protein kinase in primary neurons. J Biol Chem, 279, 34948-34956 (2004) (Pubitemid 39318131)
75. H. W. Kitamura, H. Hamanaka, M. Watanabe, K. Wada, C. Yamazaki, S. C. Fujita, T. Manabe and N. Nukina: Agedependent enhancement of hippocampal long-term potentiation in knock-in mice expressing human apolipoprotein E4 instead of mouse apolipoprotein E. Neurosci Lett, 369, 173-178 (2004) (Pubitemid 39298903)
76. P. M. Greenwood, T. Sunderland, J. L. Friz and R. Parasuraman: Genetics and visual attention: selective deficits in healthy adult carriers of the epsilon 4 allele of the apolipoprotein E gene. Proc Natl Acad Sci USA, 97, 11661-11666 (2000)
77. M. W. Bondi, D. P. Salmon, A. U. Monsch, D. Galasko, N. Butters, M. R. Klauber, L. J. Thal and T. Saitoh: Episodic memory changes are associated with the APOE-epsilon 4 allele in nondemented older adults. Neurology, 45(12), 2203-2206 (1995) (Pubitemid 27100249)
78. J. Grootendorst, A. Bour, E. Vogel, C. Kelche, P. M. Sullivan, J. C. Dodart, K. Bales and C. Mathis: Human apoE targeted replacement mouse lines: h-apoE4 and h-apoE3 mice differ on spatial memory performance and avoidance behavior. Behav Brain Res, 159, 1-14 (2005) (Pubitemid 40410579)
79. J. Raber, D. Wong, G. Q. Yu, M. Buttini, R. W. Mahley, R. E. Pitas and L. Mucke: Apolipoprotein E and cognitive performance. Nature, 404, 352-354 (2000) (Pubitemid 30164327)
80. J. Raber, D. Wong, M. Buttini, M. Orth, S. Bellosta, R. E. Pitas, R. W. Mahley and L. Mucke: Isoform-specific effects of human apolipoprotein E on brain function revealed in ApoE knockout mice: increased susceptibility of females. Proc Natl Acad Sci USA, 95, 10914-10919 (1998) (Pubitemid 28413168)
81. P. van Meer, S. Acevedo and J. Raber: Impairments in spatial memory retention of GFAP-apoE4 female mice. Behav Brain Res, 176, 372-375 (2007) (Pubitemid 44880100)
82. E. Masliah, M. Mallory, N. Ge, M. Alford, I. Veinbergs and A. D. Roses: Neurodegeneration in the central nervous system of apoE-deficient mice. Exp Neurol 136(2), 107-122 (1995)
83. D. W. Black and N. Andreasen: Schizophrenia, schizophreniform disorder, and delusional disorders. In: The American Psychiatric Press Textbook of Psychiatry. Ed R. E. Hales, S. C. Yudofsky&J. A. Talbott. American Psychiatric Press, Washington, DC (1999)
84. S. Akbarian, W. E. Bunney, Jr., S. G. Potkin, S. B. Wigal, J. O. Hagman, C. A. Sandman and E. G. Jones: Altered distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase cells in frontal lobe of schizophrenics implies disturbances of cortical development. Arch Gen Psychiatry, 50, 169-77 (1993) (Pubitemid 23077471)
85. N. C. Andreasen, S. Arndt, V. Swayze, 2nd, T. Cizadlo, M. Flaum, D. O'Leary, J. C. Ehrhardt and W. T. Yuh: Thalamic abnormalities in schizophrenia visualized through magnetic resonance image averaging. Science, 266, 294-8 (1994) (Pubitemid 24343518)
86. A. F. Arnsten and P. S. Goldman-Rakic: Noise stress impairs prefrontal cortical cognitive function in monkeys: evidence for a hyperdopaminergic mechanism. Arch Gen Psychiatry, 55, 362-368 (1998) (Pubitemid 28173626)
87. F. M. Benes: Model generation and testing to probe neural circuitry in the cingulate cortex of postmortem schizophrenic brain. Schizophr Bull, 24, 219-230 (1998) (Pubitemid 28404982)
88. F. M. Benes, J. Davidson and E. D. Bird: Quantitative cytoarchitectural studies of the cerebral cortex of schizophrenics. Arch Gen Psychiatry, 43, 31-35 (1986) (Pubitemid 16148968)
89. L. D. Selemon, G. Rajkowska and P. S. Goldman-Rakic: Elevated neuronal density in prefrontal area 46 in brains from schizophrenic patients: application of a threedimensional, stereologic counting method. J Comp Neurol, 392, 402-412 (1998) (Pubitemid 28165894)
90. B. P. Riley and P. McGuffin: Linkage and associated studies of schizophrenia. Am J Med Genet, 97, 23-44 (2000) (Pubitemid 30257324)
91. M. Tsuang: Schizophrenia: genes and environment. Biol Psychiatry, 47, 210-220 (2000) (Pubitemid 30077397)
92. S. E. Hemby, S. D. Ginsberg, B. Brunk, S. E. Arnold, J. Q. Trojanowski and J. H. Eberwine: Gene expression profile for schizophrenia: discrete neuron transcription patterns in the entorhinal cortex. Arch Gen Psychiatry, 59, 631-640 (2002) (Pubitemid 34747243)
93. S. Mexal, M. Frank, R. Berger, C. E. Adams, R. G. Ross, R. Freedman and S. Leonard: Differential modulation of gene expression in the NMDA postsynaptic density of schizophrenic and control smokers. Brain Res. Mol Brain Res, 139, 317-32 (2005) (Pubitemid 41317945)
94. M. P. Vawter, J. M. Crook, T. M. Hyde, J. E. Kleinman, D. R. Weinberger, K. G. Becker and W. J. Freed: Microarray analysis of gene expression in the prefrontal cortex in schizophrenia: a preliminary study. Schizophr Res, 58, 11-20 (2002) (Pubitemid 35287279)
95. K. Mirnics, F. A. Middleton, A. Marquez, D. A. Lewis and P. Levitt: Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex. Neuron, 28, 53-67 (2000)
96. K. Mirnics, F. A. Middleton, G. D. Stanwood, D. A. Lewis and P. Levitt: Disease-specific changes in regulator of G-protein signaling 4 (RGS4) expression in schizophrenia. Mol Psychiatry, 6, 293-301 (2001) (Pubitemid 32275674)
97. T. Hashimoto, D. W. Volk, S. M. Eggan, K. Mirnics, J. N. Pierri, Z. Sun, A. R. Sampson and D. A. Lewis: Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia. J Neurosci, 23, 6315-6326 (2003) (Pubitemid 36875633)
98. C. A. Altar, L. W. Jurata, V. Charles, A. Lemire, P. Liu, Y. Bukhman, T. A. Young, J. Bullard, H. Yokoe, M. J. Webster, M. B. Knable and J. A. Brockman: Deficient hippocampal neuron expression of proteasome, ubiquitin, and mitochondrial genes in multiple schizophrenia cohorts. Biol Psychiatry, 58, 85-96 (2005) (Pubitemid 41008124)
99. T. G. Ohm, U. Hamker, A. Cedazo-Minguez, W. Rockl, H. Scharnagl, W. Marz, R. Cowburn, W. Muller and V. Meske: Apolipoprotein E and beta A4-amyloid: signals and effects. In: Neuronal Signal Transduction and Alzheimer's Disease Ed C. Oneill&B. Anderton. Portland Press Ltd, London (2001)
100. I. Tesseur, J. Van Dorpe, K. Spittaels, C. Van den Haute, D. Moechars and F. Van Leuven: Expression of human apolipoprotein E4 in neurons causes hyperphosphorylation of protein tau in the brains of transgenic mice. Am J Pathol, 156, 951-964 (2000) (Pubitemid 30626953)
101. D. J. Stone, I. Rozovsky, T. E. Morgan, C. P. Anderson and C. E. Finch: Increased synaptic sprouting in response to estrogen via an apolipoprotein E-dependent mechanism: Implications for Alzheimer's disease. J Neurosci, 18, 3180-3185 (1998) (Pubitemid 28186010)
102. W. Liu, G. Breen, J. Zhang, S. Li, N. Gu, G. Feng, S. Bai, T. Shen, A. Yu, H. Xue, D. St Clair and L. He: Association of APOE gene with schizophrenia in Chinese: a possible risk factor in times of malnutrition. Schizophr Res 62, 225-230 (2003) (Pubitemid 36773931)
103. E. Jonsson, L. Lannfelt, B. Engvall and G. Sedvall: Lack of association between schizophrenia and the apolipoprotein E epsilon 4 allele. European Archives of Psychiatry and Clinical Neuroscience 246(4), 182-4 (1996) doi:10.1007/BF02188951 (Pubitemid 26225920)
104. S. E. Arnold, E. Joo, M. G. Martinoli, N. Roy, J. Q. Trojanowski, R. E. Gur, T. Cannon and R. A. Price: Apolipoprotein E genotype in schizophrenia: frequency, age of onset, and neuropathologic features. Neuroreport, 8, 1523-1526 (1997) (Pubitemid 27242568)
105. J. Y. Chen, C. J. Hong, H. J. Chiu, C. Y. Lin, Y. M. Bai, H. L. Song, H. C. Lai and S. J. Tsai: Apolipoprotein E genotype and schizophrenia. Neuropsychobiology, 39, 141-143 (1999)
106. B. Dean, S. M. Laws, E. Hone, K. Taddei, E. Scarr, E. A. Thomas, C. Harper, C. McClean, C. Masters, N. Lautenschlager, S. E. Gandy and R. N. Martins: Increased levels of apolipoprotein E in the frontal cortex of subjects with schizophrenia. Biol Psychiatry, 54, 616-622 (2003) (Pubitemid 41115098)
107. R. Igata-Yi, T. Igata, K. Ishizuka, T. Kimura, S. Sakamoto, S. Katsuragi, J. Takamatsu and T. Miyakawa: Apolipoprotein E genotype and psychosis. Biol Psychiatry, 41, 906-908 (1997) (Pubitemid 27158388)
108. D. Pickar, A. K. Malhotra, W. Rooney, A. Breier and D. Goldman: Apolipoprotein E epsilon 4 and clinical phenotype in schizophrenia. Lancet, 350, 930-931 (1997) (Pubitemid 27420533)
109. M. Rietschel, H. Krauss, D. J. Muller, M. M. Nothen and F. Macciardi: Apolipoprotein E epsilon 4 and clinical phenotype in schizophrenia. Lancet, 350, 1857-1858 (1997) (Pubitemid 28036540)
110. A. K. Malhotra, A. Breier, D. Goldman, L. Picken and D. Pickar: The apolipoprotein E epsilon 4 allele is associated with blunting of ketamine-induced psychosis in schizophrenia. A preliminary report. Neuropsychopharmacology, 19, 445-448 (1998) (Pubitemid 28451600)
111. L. Martorell, C. Virgos, J. Valero, G. Coll, L. Figuera, J. Joven, M. Pocovi, A. Labad and E. Vilella: Schizophrenic women with the APOE epsilon 4 allele have a worse prognosis than those without it. Mol Psychiatry, 6, 307-310 (2001) (Pubitemid 32275676)
112. A. O. Akanji, J. U. Ohaeri, S. N. Al-Shammri and H. R. Fatania: Apolipoprotein E polymorphism and clinical disease phenotypes in Arab patients with schizophrenia. Neuropsychobiology, 60, 67-72 (2009)
113. F. Schurhoff, M. O. Krebs, A. Szoke, J. Y. Loze, C. Goldberger, V. Quignon, J. Tignol, F. Rouillon, J. L. Laplanche and M. Leboyer: Apolipoprotein E in schizophrenia: a French association study and meta-analysis. Am J Med Genet B. Neuropsychiatr Genet 119B, 18-23 (2003) (Pubitemid 37064047)
114. M. Q. Xu, D. St Clair and L. He: Meta-analysis of association between ApoE epsilon4 allele and schizophrenia. Schizophr Res 84(2-3), 228-235 (2006)
115. D. St Clair, M. Xu, P. Wang, Y. Yu, Y. Fang, F. Zhang, X. Zheng, N. Gu, G. Feng, P. Sham and L. He: Rates of adult schizophrenia following prenatal exposure to the Chinese famine of 1959-1961. J Am Med Assoc, 294, 557-562 (2005) (Pubitemid 41126897)
116. T. Kimura, M. Shono, S. Yokota, R. Igata-Yi, J. Takamatsu and T. Miyakawa: Apolipoprotein E epsilon3 allele is not a risk factor of schizophrenia: a study of 314 Japanese patients. Neuropsychobiology, 42, 66-68 (2000) (Pubitemid 30665978)
117. L. Martorell, J. Costas, J. Valero, A. Gutierrez-Zotes, C. Phillips, M. Torres, A. Brunet, G. Garrido, A. Carracedo, R. Guillamat, V. Valles, M. Guitart, A. Labad and E. Vilella: Analyses of variants located in estrogen metabolism genes (ESR1, ESR2, COMT and APOE) and schizophrenia. Schizophr Res, 100), 308-315 (2008)
118. S. Sorbi, B. Nacmias, A. Tedde, S. Latorraca, P. Forleo, B. M. Guarnieri, C. Petruzzi, E. Daneluzzo, L. Ortenzi, S. Piacentini and L. Amaducci: No implication of apolipoprotein E polymorphism in Italian schizophrenic patients. Neurosci Lett 244(2), 118-120 (1998) (Pubitemid 28157406)
119. N. Durany, P. Riederer and F. F. Cruz-Sanchez: Apolipoprotein E genotype in Spanish schizophrenic patients. Psychiatr Genet, 10, 73-77 (2000) (Pubitemid 32000903)
120. O. Kampman, S. Anttila, A. Illi, K. M. Mattila, R. Rontu, E. Leinonen and T. Lehtimaki: Apolipoprotein E polymorphism is associated with age of onset in schizophrenia. J Hum Genet, 49(7), 355-359 (2004) (Pubitemid 39045033)
121. C. Tovilla-Zarate, B. C. Medellin, A. Fresan, R. Apiquian, A. Dassori, M. Rolando, M. Escamilla and H. Nicolini: APOEepsilon3 and APOE-219G haplotypes increase the risk for schizophrenia in sibling pairs. J Neuropsychiatry Clin Neurosci, 21, 440-444 (2009)
122. M. K. Lee, A. J. Park, B. Y. Nam, K. J. Min, B. S. Kee and D. B. Park: Apolipoprotein E genotype in Korean schizophrenic patients. J Korean Med Sci 16, 781-783 (2001) (Pubitemid 33741068)
123. B. Dean, S. M. Laws, E. Hone, K. Taddei, E. Scarr, E. A. Thomas, C. Harper, C. McClean, C. Masters, N. Lautenschlager, S. E. Gandy and R. N. Martins: Increased levels of apolipoprotein E in the frontal cortex of subjects with schizophrenia. Biol Psychiatry, 54, 616-622 (2003) (Pubitemid 41115098)
124. B. L. Plassman, K. A. WelshBohmer, E. D. Bigler, S. C. Johnson, C. V. Anderson, M. J. Helms, A. M. Saunders and J. C. S. Breitner: Apolipoprotein E epsilon 4 allele and hippocampal volume in twins with normal cognition. Neurology, 48, 985-989 (1997)
125. T. Hata, H. Kunugi, S. Nanko, R. Fukuda and T. Kaminaga: Possible effect of the APOE epsilon 4 allele on the hippocampal volume and asymmetry in schizophrenia. Am J Med Genet, 114, 641-642 (2002)
126. T. Fernandez, W. L. Yan, S. Hamburger, J. L. Rapoport, A. M. Saunders, M. Schapiro, E. I. Ginns and E. Sidransky: Apolipoprotein E alleles in childhood-onset schizophrenia. Am J Med Genet 88, 211-213 (1999) (Pubitemid 29156462)
127. D. Horrobin: The lipid hypothesis of schizophrenia. In: Brain Lipids and Disorders in Biological Psychiatry Ed E. R. Skinner. Elsevier Science, Amsterdam (2002)
128. P. F. Boston, S. M. Dursun, R. Zafar and M. A. Reveley: Serum cholesterol and treatment-resistance in schizophrenia. Biol Psychiatry, 40, 542-543 (1996) (Pubitemid 26319621)
129. M. C. Royston, R. Bell, D. Collier, R. W. Kerwin and G. W. Roberts: Apolipoprotein E and schizophrenia: association with clinical response to clozapine. Schizophr Res, 24, 93-94 (1997)
130. M. Miyata and J. D. Smith: Apolipoprotein E allelespecific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nature Genet, 14, 55-61 (1996) (Pubitemid 26301547)
131. S. P. Mahadik and S. Mukherjee: Free radical pathology and antioxidant defense in schizophrenia: a review. Schizophr Res, 19, 1-17 (1996) (Pubitemid 26133208)
132. S. P. Mahadik and R. E. Scheffer: Oxidative injury and potential use of antioxidants in schizophrenia. Prostaglandins Leukot Essent Fatty Acids. 55, 45-54 (1996) (Pubitemid 26321117)
133. N. Nishioka and S. E. Arnold: Evidence for oxidative DNA damage in the hippocampus of elderly patients with chronic schizophrenia. Am J Geriatr Psychiatry, 12, 167-175 (2004) (Pubitemid 38250300)
134. A. Lin, G. Kenis, S. Bignotti, G. J. Tura, R. De Jong, E. Bosmans, R. Pioli, C. Altamura, S. Scharpe and M. Maes: The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. Schizophr Res, 32, 9-15 (1998) (Pubitemid 28338119)
135. M. Maes, H. Y. Meltzer, P. Buckley and E. Bosmans: Plasma-soluble interleukin-2 and transferrin receptor in schizophrenia and major depression. Eur Arch Psychiatry. Clin Neurosci, 244, 325-329 (1995)
136. G. R. Parker, H. M. Cathcart, R. Huang, I. S. Lanham, E. H. Corder and S. E. Poduslo: Apolipoprotein gene E4 allele promoter polymorphisms as risk factors for Alzheimer's disease. Psychiatr Genet, 15, 271-275 (2005) (Pubitemid 44491465)
137. S. M. Laws, K. Taddei, G. Martins, A. Paton, C. Fisher, R. Clarnette, J. Hallmayer, W. S. Brooks, S. E. Gandy and R. N. Martins: The -491AA polymorphism in the APOE gene is associated with increased plasma apoE levels in Alzheimer's disease. Neuroreport, 10, 879-882 (1999) (Pubitemid 29393839)
138. S. M. Laws, E. Hone, K. Taddei, C. Harper, B. Dean, C. McClean, C. Masters, N. Lautenschlager, S. E. Gandy and R. N. Martins: Variation at the APOE-491 promoter locus is associated with altered brain levels of apolipoprotein E. Mol Psychiatry, 7, 886-890 (2002)
139. T. Shinkai, O. Ohmori, H. Kojima, T. Terao, T. Suzuki, K. Abe and J. Nakamura: Apolipoprotein E regulatory region genotype in schizophrenia. Neurosci Lett, 256, 57-60 (1998) (Pubitemid 28535403)
140. A. Digney, D. Keriakous, E. Scarr, E. Thomas and B. Dean: Differential changes in apolipoprotein E in schizophrenia and bipolar I disorder. Biol Psychiatr,y 57, 711-715 (2005) (Pubitemid 40487914)
141. A. S. Gibbons, E. A. Thomas, E. Scarr and B. Dean: Low density lipoprotein receptor-related protein and Apolipoprotein E expression is altered in schizophrenia. Front Mol Psychiatry, 1, 19 (2010)
142. B. Dean, A. Digney, S. Sundram, E. Thomas and E. Scarr: Plasma apolipoprotein E is decreased in schizophrenia spectrum and bipolar disorder. Psychiatry Res, 158, 75-78 (2008)
143. M. Sjobeck, M. Haglund and E. Englund: Decreasing myelin density reflected increasing white matter pathology in Alzheimer's disease - a neuropathological study. Int J Geriatr Psychiatry, 20, 919-926 (2005) (Pubitemid 43055103)
144. G. Bartzokis, P. H. Lu, D. H. Geschwind, K. Tingus, D. Huang, M. F. Mendez, N. Edwards and J. Mintz: Apolipoprotein e affects both myelin breakdown and cognition: Implications for age-related trajectories of decline into dementia. Biol Psychiatry, 62, 1380-1387 (2007) (Pubitemid 350180726)
145. N. Uranova, D. Orlovskaya, O. Vikhreva, I. Zimina, N. Kolomeets, V. Vostrikov and V. Rachmanova: Electron microscopy of oligodendroglia in severe mental illness. Brain Res Bull, 55, 597-610 (2001) (Pubitemid 32888378)
146. N. A. Uranova, V. M. Vostrikov, D. D. Orlovskaya and V. I. Rachmanova: Oligodendroglial density in the prefrontal cortex in schizophrenia and mood disorders: a study from the Stanley Neuropathology Consortium. Schizophr Res, 67, 269-275 (2004) (Pubitemid 38251458)
147. Y. Hakak, J. R. Walker, C. Li, W. H. Wong, K. L. Davis, J. D. Buxbaum, V. Haroutunian and A. A. Fienberg: Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci USA, 98, 4746-4751 (2001) (Pubitemid 32295047)
148. J. F. Goodrum: Cholesterol from degenerating nerve myelin becomes associated with lipoproteins containing Apolipoprotein-E. J Neurochem, 56, 2082-2086 (1991)
149. A. Akahane, H. Kunugi, H. Tanaka and S. Nanko: Association analysis of polymorphic CGG repeat in 5' UTR of the reelin and VLDLR genes with schizophrenia. Schizophr Res,58, 37-41 (2002) (Pubitemid 35287281)
150. K. Suzuki, K. Nakamura, Y. Iwata, Y. Sekine, M. Kawai, G. Sugihara, K. J. Tsuchiya, S. Suda, H. Matsuzaki, N. Takei, K. Hashimoto and N. Mori: Decreased expression of reelin receptor VLDLR in peripheral lymphocytes of drug-naive schizophrenic patients. Schizophr Res, 98, 148-156 (2008) (Pubitemid 350235901)
151. S. Narayan, B. Tang, S. R. Head, T. J. Gilmartin, J. G. Sutcliffe, B. Dean and E. A. Thomas: Molecular profiles of schizophrenia in the CNS at different stages of illness. Brain Res, 1239, 235-248 (2008)
152. G. D'Arcangelo, G. G. Miao, S. C. Chen, H. D. Soares, J. I. Morgan and T. Curran: A protein related to extracellular matrix proteins deleted in the mouse mutant reeler. Nature, 374, 719-723 (1995)
153. A. M. Goffinet: An early development defect in the cerebral cortex of the reeler mouse. A morphological study leading to a hypothesis concerning the action of the mutant gene. Anat Embryol (Berl), 157, 205-216 (1979) (Pubitemid 10192068)
154. M. Ogawa, T. Miyata, K. Nakajima, K. Yagyu, M. Seike, K. Ikenaka, H. Yamamoto and K. Mikoshiba: The reeler geneassociated antigen on Cajal-Retzius neurons is a crucial molecule for laminar organization of cortical neurons. Neuron, 14, 899-912 (1995)
155. S. Qiu, K. M. Korwek and E. J. Weeber: A fresh look at an ancient receptor family: emerging roles for low density lipoprotein receptors in synaptic plasticity and memory formation. Neurobiol Learn Mem, 85, 16-29 (2006) (Pubitemid 41786046)
156. J. Herz and Y. Chen: Reelin, lipoprotein receptors and synaptic plasticity. Nature Rev Neurosci, 7, 850-859 (2006) (Pubitemid 44624177)
157. M. A. Rodriguez, C. Pesold, W. S. Liu, V. Kriho, A. Guidotti, G. D. Pappas and E. Costa: Colocalization of integrin receptors and reelin in dendritic spine postsynaptic densities of adult nonhuman primate cortex. Proc Natl Acad Sci USA, 97, 3550-3555 (2000) (Pubitemid 30183340)
158. S. L. Eastwood and P. J. Harrison: Cellular basis of reduced cortical reelin expression in schizophrenia. Am J Psychiatry, 163, 540-542 (2006) (Pubitemid 44469402)
159. S. H. Fatemi, J. A. Earle and T. McMenomy: Reduction in Reelin immunoreactivity in hippocampus of subjects with schizophrenia, bipolar disorder and major depression. Mol Psychiatry, 5, 654-663 (2000)
160. A. Guidotti, J. Auta, J. M. Davis, V. Di-Giorgi-Gerevini, Y. Dwivedi, D. R. Grayson, F. Impagnatiello, G. Pandey, C. Pesold, R. Sharma, D. Uzunov and E. Costa: Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study. Arch Gen Psychiatry, 57, 1061-1069 (2000)
161. E. F. Torrey, B. M. Barci, M. J. Webster, J. J. Bartko, J. H. Meador-Woodruff and M. B. Knable: Neurochemical markers for schizophrenia, bipolar disorder, and major depression in postmortem brains. Biol Psychiatry, 57, 252-260 (2005) (Pubitemid 40187369)
162. V. Borrell, J. A. Del Rio, S. Alcantara, M. Derer, A. Martinez, G. D'Arcangelo, K. Nakajima, K. Mikoshiba, P. Derer, T. Curran and E. Soriano: Reelin regulates the development and synaptogenesis of the layer-specific entorhino-hippocampal connections. J Neurosci, 19, 1345-1358 (1999) (Pubitemid 29088917)
163. J. Larson, J. S. Hoffman, A. Guidotti and E. Costa: Olfactory discrimination learning deficit in heterozygous reeler mice. Brain Res, 971, 40-46 (2003) (Pubitemid 36412062)
164. W. S. Liu, C. Pesold, M. A. Rodriguez, G. Carboni, J. Auta, P. Lacor, J. Larson, B. G. Condie, A. Guidotti and E. Costa: Down-regulation of dendritic spine and glutamic acid decarboxylase 67 expressions in the reelin haploinsufficient heterozygous reeler mouse. Proc Natl Acad Sci USA, 98, 3477-3482 (2001) (Pubitemid 32220870)
165. N. R. Smalheiser, E. Costa, A. Guidotti, F. Impagnatiello, J. Auta, P. Lacor, V. Kriho and G. D. Pappas: Expression of reelin in adult mammalian blood, liver, pituitary pars intermedia, and adrenal chromaffin cells. Proc Natl Acad Sci USA, 97, 1281-1286 (2000) (Pubitemid 30080850)
166. P. Tueting, E. Costa, Y. Dwivedi, A. Guidotti, F. Impagnatiello, R. Manev and C. Pesold: The phenotypic characteristics of heterozygous reeler mouse. Neuroreport, 10, 1329-1334 (1999) (Pubitemid 29403718)
167. T. Curran and G. D'Arcangelo: Role of reelin in the control of brain development. Brain Res. Brain Res Rev 26, 285-294 (1998) (Pubitemid 28318083)
168. M. Trommsdorff, M. Gotthardt, T. Hiesberger, J. Shelton, W. Stockinger, J. Nimpf, R. E. Hammer, J. A. Richardson and J. Herz: Reeler/Disabled-like disruption of neuronal migration in knockout mice lacking the VLDL receptor and ApoE receptor 2. Cell, 97, 689-701 (1999) (Pubitemid 29278044)
169. D. R. Grayson, Y. Chen, E. Costa, E. Dong, A. Guidotti, M. Kundakovic and R. P. Sharma: The human reelin gene: transcription factors (+), repressors (-) and the methylation switch (+/-) in schizophrenia. Pharmacol Therapy, 111, 272-286 (2006) (Pubitemid 43765535)
170. D. R. Grayson, X. Jia, Y. Chen, R. P. Sharma, C. P. Mitchell, A. Guidotti and E. Costa: Reelin promoter hypermethylation in schizophrenia. Proc Natl Acad Sci USA, 102, 9341-9346 (2005) (Pubitemid 40923565)
171. L. Tremolizzo, G. Carboni, W. B. Ruzicka, C. P. Mitchell, I. Sugaya, P. Tueting, R. Sharma, D. R. Grayson, E. Costa and A. Guidotti: An epigenetic mouse model for molecular and behavioral neuropathologies related to schizophrenia vulnerability. Proc Natl Acad Sci USA, 99, 17095-17100 (2002) (Pubitemid 36034104)
172. L. Tremolizzo, M. S. Doueiri, E. Dong, D. R. Grayson, J. Davis, G. Pinna, P. Tueting, V. Rodriguez-Menendez, E. Costa and A. Guidotti: Valproate corrects the schizophrenia-like epigenetic behavioral modifications induced by methionine in mice. Biol Psychiatry, 57, 500-9 (2005) (Pubitemid 40311985)
173. C. Schwarz, A. Volz, C. B. Li and S. Leucht: Valproate for schizophrenia. Cochrane Database Syst Rev, 3, Cd004028 (2008)
174. S. H. Fatemi, J. L. Kroll and J. M. Stary: Altered levels of Reelin and its isoforms in schizophrenia and mood disorders. Neuroreport 12, 3209-3215 (2001) (Pubitemid 33010645)
175. L. V. Kessing and O. S. Jørgensen: Apolipoprotein E-[varepsilon]4 frequency in affective disorder. Biol Psychiatry, 45, 430-434 (1999) (Pubitemid 29130441)
176. F. Bellivier, J.-L. Laplanche, F. Schürhoff, J. Feingold, A. Féline, R. Jouvent, J.-M. Launay and M. Leboyer: Apolipoprotein E gene polymorphism in early and late onset bipolar patients. Neurosci Lett, 233, 45-48 (1997) (Pubitemid 27402549)
177. P. A. Gochee, E. E. Powell, D. M. Purdie, N. Pandeya, L. Kelemen, C. Shorthouse, J. R. Jonsson and B. Kelly: Association Between Apolipoprotein E {epsilon}4 and Neuropsychiatric Symptoms During Interferon α Treatment for Chronic Hepatitis C. Psychosomatics, 45, 49-57 (2004) (Pubitemid 38082507)
178. M. Miyata and J. D. Smith: Apolipoprotein E allelespecific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nature Genet, 14, 55-61 (1996) (Pubitemid 26301547)
179. P. L. Fan, C. D. Chen, W. T. Kao, B. C. Shu and F. W. Lung: Protective effect of the apo e2 allele in major depressive disorder in Taiwanese. Acta Psychiatr Scand, 113, 48-53 (2006)
180. S. Lopez-Leon, A. C. Janssens, A. M. Gonzalez-Zuloeta Ladd, J. Del-Favero, S. J. Claes, B. A. Oostra and C. M. van Duijn: Meta-analyses of genetic studies on major depressive disorder. Mol Psychiatry, 13, 772-785 (2008) (Pubitemid 352032108)
181. A. Digney, D. Keriakous, E. Scarr, E. Thomas and B. Dean: Differential changes in apolipoprotein E in schizophrenia and bipolar I disorder. Biol Psychiatry, 57, 711-715 (2005) (Pubitemid 40487914)
182. B. Dean, A. Digney, S. Sundram, E. Thomas and E. Scarr: Plasma apolipoprotein E is decreased in schizophrenia spectrum and bipolar disorder. Psychiatry Res 158(1), 75-78 (2008)
183. R. J. Schloesser, J. Huang, P. S. Klein and H. K. Manji: Cellular plasticity cascades in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology, 33, 110-133 (2008) (Pubitemid 350191320)
184. C. Pittenger and R. S. Duman: Stress, depression, and neuroplasticity: A convergence of mechanisms. Neuropsychopharmacology, 33, 88-109 (2008) (Pubitemid 350191319)
185. D. C. Henderson: Schizophrenia and comorbid metabolic disorders. J Clin Psychiatry, 66 Suppl, 11-20 (2005) (Pubitemid 41243257)
186. N. Richter, G. Juckel and H. J. Assion: Metabolic syndrome: a follow-up study of acute depressive inpatients. Eur Arch Psychiatry. Clin Neurosci, 260, 41-49 (2009)
187. P. J. Weiden, J. A. Mackell and D. D. McDonnell: Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res 66, 51-57 (2004) (Pubitemid 38030344)
188. J. Gao, H. Katagiri, Y. Ishigaki, T. Yamada, T. Ogihara, J. Imai, K. Uno, Y. Hasegawa, M. Kanzaki, T. T. Yamamoto, S. Ishibashi and Y. Oka: Involvement of apolipoprotein E in excess fat accumulation and insulin resistance. Diabetes, 56, 24-33 (2007)
189. A. Sima, A. Iordan and C. Stancu: Apolipoprotein E polymorphism - a risk factor for metabolic syndrome. Clin Chem Lab Med 45, 1149-1153 (2007) (Pubitemid 47396270)
190. K. S. Lee, Y. Jang, Y.-K. Chung, J. H. Chung, B. H. Oh and C. H. Hong: Relationship between the diagnostic components of metabolic syndrome (MS) and cognition by ApoE genotype in the elderly. Arch Gerontol Geriatr, 50, 69-72 (2009)
191. D. E. Casey: Dyslipidemia and atypical antipsychotic drugs. J Clin Psychiatry, 65, 27-35 (2004)
192. H. Pijl and A. E. Meinders: Bodyweight change as an adverse effect of drug treatment - Mechanisms and management. Drug Safety 14, 329-342 (1996)
193. J. de Leon, F. J. Diaz, R. C. Josiassen, T. B. Cooper and G. M. Simpson: Weight gain during a double-blind multiclosage clozapine study. Journal of Clinical Psychopharmacology, 27, 22-27 (2007) (Pubitemid 46105759)
194. B. R. Basson, B. J. Kinon, C. C. Taylor, K. A. Szymanski, J. A. Gilmore and G. D. Tollefson: Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J Clini Psychiatry, 62, 231-238 (2001) (Pubitemid 32428761)
195. S. K. Verma, M. Subramaniam, A. Liew and L. Y. Poon: Metabolic Risk Factors in Drug-Naive Patients With First-Episode Psychosis. J Clin Psychiatry, 70, 997-1000 (2009)
196. H.-M. Alanen, H. Finne-Soveri and E. Leinonen: Factors associated with non-use of antipsychotics among older residents with schizophrenia in long-term institutional care. Int J Geriatr Psychiatry, 23, 1261-1265 (2008)
197. S. Zammit, F. Rasmussen, B. Farahmand, D. Gunnell, G. Lewis, P. Tynelius and G. P. Brobert: Height and body mass index in young adulthood and risk of schizophrenia: a longitudinal study of 1 347 520 Swedish men. Acta Psychiatr Scand 116(5), 378-385 (2007) (Pubitemid 47537422)
198. R. Amani: Is dietary pattern of schizophrenia patients different from healthy subjects? BMC Psychiatry 7, 15 (2007)
199. A. M. Kilbourne, D. L. Rofey, J. F. McCarthy, E. P. Post, D. Welsh and F. C. Blow: Nutrition and exercise behavior among patients with bipolar disorder. Bipolar Disord, 9, 443-452 (2007) (Pubitemid 47202506)
200. C. J. Hong, Y. W. Yu, C. H. Lin, H. L. Song, H. C. Lai, K. H. Yang and S. J. Tsai: Association study of apolipoprotein E epsilon4 with clinical phenotype and clozapine response in schizophrenia. Neuropsychobiology, 42(4), 172-174 (2000)
201. G. M. Murphy, C. Kremer, H. Rodrigues, A. F. Schatzberg and S. Mirtazapine versus Paroxetine: The apolipoprotein E epsilon 4 allele and antidepressant efficacy in cognitively intact elderly depressed patients. Biol Psychiatry, 54, 665-673 (2003) (Pubitemid 37281381)
202. D. Clark, O. A. Skrobot, I. Adebiyi, M. T. Susce, J. de Leon, A. F. Blakemore and M. J. Arranz: Apolipoprotein-E gene variants associated with cardiovascular risk factors in antipsychotic recipients. Eur Psychiatry, 24, 456-463 (2009)